Side-by-side · Research reference

MazdutidevsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED19/62 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

Mazdutide

GLP-1/Glucagon Dual Agonist · Oxyntomodulin Analogue · Phase 3

9 mgWeekly doseJi 2026

12.4%Weight lossAzam 2026

Phase 3Status (China)

SQ · Abdomen · Once WeeklyJi 2026

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

Mazdutide

Vesugen

Primary target

GLP-1 receptor and glucagon receptorAbdul 2026 Elmendorf 2026

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

Dual agonism: GLP-1R → satiety, insulin secretion, gastric emptying delay; GCGR → hepatic lipolysis, energy expenditure, thermogenesisElmendorf 2026 Abulehia 2026

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Weight loss via appetite suppression (GLP-1 axis) and increased energy expenditure (glucagon axis); improved glycemic control in T2D

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

Yes — physiological receptor-mediated signaling preserved

Not applicable — does not operate via hormone axis

Origin

Synthetic oxyntomodulin analogue — endogenous peptide with dual GLP-1/glucagon activity

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

Mazdutide

Vesugen

Phase 2 studied dose

9 mg / weekJi 2026

Highest efficacy dose in obesity trial (BMI ≥30 kg/m²).Ji 2026

—

Frequency

Once weeklyJi 2026 Luo 2026

Not specified in available literature

Route

SubcutaneousJi 2026

Subcutaneous or intramuscular

Dose escalation

3 mg → 6 mg → 9 mg (titration schedule in trials)

Gradual escalation to minimize GI side effects.

—

Evidence basis

Phase 2 RCT / Phase 3 ongoingJi 2026 Luo 2026

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Duration (trials)

24–48 weeks

—

Population

Non-diabetic adults BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities

—

Phase 3 comparator

Semaglutide 1 mg/week (DREAMS-3 trial)Luo 2026

—

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Duration

—

Case series report treatment courses in elderly arterial insufficiency

Half-life

—

Not reported

Tripeptides typically cleared rapidly.

03Metabolic / Fat Loss Evidence

Parameter

Mazdutide

Vesugen

Percentage body weight loss

12.4% (pooled meta-analysis, 9 mg dose)

95% CI: -16.15% to -8.68%, random-effects model.Azam 2026

—

Absolute weight loss

9.8 kg (mean)Azam 2026

95% CI: -13.15 to -6.37 kg.Azam 2026

—

Responder rate (≥10% loss)

Not explicitly reported in available abstracts

—

Mechanism

Appetite suppression (GLP-1) + energy expenditure (glucagon)Elmendorf 2026

—

BMI reduction

Significant reduction in Chinese adults BMI ≥30 kg/m²Ji 2026

—

Visceral fat

Expected benefit from glucagon-mediated lipolysis (not quantified in abstracts)

—

Glycemic improvement

HbA1c reduction in T2D cohort (Phase 3 DREAMS-3)

—

Comparator efficacy

Head-to-head vs semaglutide 1 mg (Phase 3 pending publication)Luo 2026

—

Key publications

Ji et al. Med 2026 · Azam et al. Diab Obes Metab 2026 · Luo et al. Contemp Clin Trials 2026

—

04Side Effects & Safety

Parameter

Mazdutide

Vesugen

Gastrointestinal symptoms

Nausea, vomiting, diarrhea (most common, GLP-1 effect)

—

Injection site reactions

Erythema, pruritus, local discomfort

—

Hypoglycemia

Low risk in non-diabetic cohort; monitor in T2D with insulin or sulfonylureas

—

Cardiovascular effects

Increased heart rate (glucagon effect, transient)

—

Pancreatitis risk

Theoretical (incretin class effect); monitor amylase/lipase if abdominal pain

—

Thyroid C-cell tumors

Black box warning for GLP-1 class (rodent data); human relevance unclear

—

Gallbladder disease

Cholelithiasis, cholecystitis (rapid weight loss effect)

—

Tolerability

Generally well-tolerated; GI effects diminish with dose titration

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

Mazdutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2 (MEN 2)
·Hypersensitivity to mazdutide or excipients
·Pregnancy

Vesugen

—

Relative Contraindications

Mazdutide

·History of pancreatitis
·Severe gastroparesis or GI motility disorders
·Diabetic retinopathy (monitor, risk of worsening with rapid glycemic change)
·Renal impairment (limited data, use with caution)

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

Mazdutide

Vesugen

1. Preparation

Supplied as pre-filled pen or reconstituted vial (per manufacturer instructions). Inspect solution — should be clear, colorless to pale yellow. Discard if cloudy or particulate matter present.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Injection site

Subcutaneous — abdomen preferred, also thigh or upper arm. Rotate sites weekly. Avoid areas with scarring, moles, or active inflammation.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Timing

Once weekly, same day each week. May be taken with or without food. If dose missed, administer within 3 days; if >3 days, skip and resume next scheduled dose.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Storage

Refrigerate 2–8 °C. Do not freeze. May be kept at room temperature (<25 °C) for up to 14 days if needed. Protect from light.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

5. Needle technique

Use supplied needle or compatible insulin syringe (if reconstituting). Pinch skin, inject at 90° angle. Hold 5–10 seconds before withdrawing needle to prevent leakage.

—

06Stack Synergy

Mazdutide

— no documented stacks

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)